Cardiol Therapeutics Inc. - Class A Common Shares (NQ:CRDL)

1.150 +0.010 (+0.88%)

Delayed Quote Updated: 1:16 PM EDT, Oct 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Cardiol Therapeutics Inc. - Class A Common Shares

< Previous 1 2 3 4 Next >

Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients

June 17, 2024

In a phenomenal year marked by over +180% gains in its stock price, Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) added another feather to its cap last week with the announcement of its Phase II...

Via TheNewswire.com

Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients

June 17, 2024

Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients

Via News Direct

Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis

June 13, 2024

Administration of CardiolRx™ led to a marked reduction in the primary efficacy endpoint of pericarditis painCardiolRx™ also shown to reduce...

Via Newsfile

Sector Spotlight: Orphan Drug Developers With Significant Upside

June 03, 2024

Via AB Newswire

Topics ETFs

Sector Spotlight: Orphan Drug Developers With Significant Upside

June 03, 2024

The biotech sector is finally beginning to recover following a two year stretch of underperformance that was largely driven by rising interest rates and other macro factors. Biotech has a track record...

Via TheNewswire.com

Topics ETFs

Stocks That Hit 52-Week Lows On Wednesday ↗

October 19, 2022

On Wednesday, 200 companies hit new 52-week lows.

Via Benzinga

Analysts Consensus Reaffirms Significant Upside Potential for Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL)

May 28, 2024

Via AB Newswire

Analysts’ Consensus Reaffirms Significant Upside Potential for Cardiol Therapeutics

May 28, 2024

Analysts’ Consensus Reaffirms Significant Upside Potential for Cardiol Therapeutics

Via News Direct

CRDL Stock Earnings: Cardiol Therapeutics Meets EPS for Q1 2024 ↗

May 14, 2024

CRDL stock results show that Cardiol Therapeutics met analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In ↗

May 14, 2024

Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028.

Via Benzinga

Topics Cannabis

CRDL Stock Earnings: Cardiol Therapeutics Beats EPS for Q4 2023 ↗

April 02, 2024

CRDL stock results show that Cardiol Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.

Via InvestorPlace

Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis

February 21, 2024

This is a Designated News Release.Toronto, Ontario--(Newsfile Corp. - February 21, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL)...

Via Newsfile

Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis

February 15, 2024

This is a Designated News Release.Toronto, Ontario--(Newsfile Corp. - February 15, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL)...

Via Newsfile

Cardiol Therapeutics - This Penny Stock Is An Analysts Favorite ↗

January 31, 2024

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies.

Via Talk Markets

Cardiol Therapeutics Announces It Has Exceeded 50% Enrollment in Its Phase II MAvERIC-Pilot Study in Recurrent Pericarditis

November 01, 2023

Toronto, Ontario--(Newsfile Corp. - November 1, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a...

Via Newsfile

Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases

October 13, 2023

Via Get News

Topics Death

Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases

October 13, 2023

--News Direct--

Via News Direct

Topics Death

Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases

October 13, 2023

Toronto, ON, October 13, 2013 (PlatoData via 500NewsWire) -- In the United States, heart disease accounts for a significant number of deaths every year, with cardiovascular disease being the primary...

Via TheNewswire.com

Topics Death

Cardiol Therapeutics Fights Heart Inflammation With Novel Formulations ↗

October 12, 2023

697,000 people die from heart disease every year in the United States – that is one in every five deaths.

Via Benzinga

CBD To Treat Heart Failure? New Study Shows Its Cardioprotective Effects ↗

October 10, 2023

On Tuesday, Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) announced positive study results demonstrating that subcutaneously administered cannabidiol - the active pharmaceutical ingredient in...

Via Benzinga

Cardiol Therapeutics Announces Positive Study Results Demonstrating Cardioprotective Effects of Subcutaneously Administered Cannabidiol in a Model of Heart Failure with Preserved Ejection Fraction

October 10, 2023

Results Demonstrate the Active Pharmaceutical Ingredient in Cardiol's Novel CRD-38 Formulation Attenuates Harmful Fat Distribution and Key Markers of Cardiac...

Via Newsfile

Why Murphy Canyon Acquisition Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket ↗

September 21, 2023

Gainers Near Intelligence, Inc. (NASDAQ: NIR) shares rose 34.1% to $0.2801 in pre-market trading after falling 42% on Wednesday. Near Intelligence recently named its General Counsel, Jay Angelo, to...

Via Benzinga

Cardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in ARCHER, a Phase II Trial of CardiolRx(TM) for the Treatment of Acute Myocarditis

September 19, 2023

Recruitment Accelerating and Full Patient Enrollment Anticipated to be Completed During Q3 2024, up to Six Months Ahead of Schedule Multi-Center,...

Via Newsfile

Sidoti's Micro-Cap Virtual May Conference

May 09, 2023

Via ACCESSWIRE

Stocks That Hit 52-Week Lows On Tuesday ↗

October 18, 2022

During Tuesday's session, 78 companies made new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

October 04, 2022

On Tuesday, 44 companies hit new 52-week lows.

Via Benzinga

Cardiol Therapeutics Announces Poster Presentation at The Annual Scientific Meeting of the Heart Failure Society of America

September 28, 2022

Oakville, Ontario--(Newsfile Corp. - September 28, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a...

Via Newsfile

Hot Debate Over Myocarditis Risk Shines Spotlight on Heart Disease

July 26, 2022

Palm Beach, FL – July 26, 2022 – FinancialNewsMedia.com News Commentary – As COVID-19 vaccines for kids achieve the Centers for Disease Control and Prevention (CDC) recommendation, concern it could...

Via FinancialNewsMedia

Air Pollution is a Global Heart and Lung Health Concern

July 18, 2022

Palm Beach, FL – July 18, 2022 – FinancialNewsMedia.com News Commentary – Particulate matter or particle pollution is a significant contributor to heart and lung disease. Individuals most affected by...

Via FinancialNewsMedia

Topics Climate Change Emissions Energy

The Healthcare Companies Fighting the World’s Biggest Killers

July 13, 2022

Palm Beach, FL – July 13, 2022 – FinancialNewsMedia.com News Commentary – Some of the most prevalent health conditions on the planet claim millions of lives every year. Companies from across the...

Via FinancialNewsMedia

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.